Physician profile
Rahul Bajaj
NPI 1174553135
$5,016.57
in general payments reported to CMS, 2019-2025
37 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $157 · 2021: $576 · 2022: $376 · 2023: $808 · 2024: $1,140 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,571.59 | 2019-2025 | Viberzi, Linzess, Rinvoq |
| Medtronic, INC. | $317.10 | 2024 | Signia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.35 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $269.03 | 2019-2025 | Eohilia, Entyvio |
| Janssen Biotech, INC. | $190.86 | 2019-2025 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $180.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $172.53 | 2023-2025 | Ibsrela |
| Allergan, INC. | $167.44 | 2019 | |
| Boston Scientific Corporation | $160.79 | 2025 | Axios, Hydra Jagwire |
| Davol INC. | $159.95 | 2023 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $145.13 | 2019-2023 | Dificid |
| Genzyme Corporation | $132.45 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $126.47 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $123.24 | 2021 | |
| Celgene Corporation | $115.76 | 2021-2024 | Zeposia |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.